This company is no longer active
0P0 Stock Overview
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aerie Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.50 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$4.58 |
| Beta | -0.062 |
| 1 Month Change | -5.23% |
| 3 Month Change | 33.03% |
| 1 Year Change | 63.84% |
| 3 Year Change | -14.71% |
| 5 Year Change | -71.88% |
| Change since IPO | 16.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0P0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -2.3% |
| 1Y | 63.8% | -20.9% | 9.0% |
Return vs Industry: 0P0 exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Return vs Market: 0P0 exceeded the German Market which returned -21.6% over the past year.
Price Volatility
| 0P0 volatility | |
|---|---|
| 0P0 Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 0P0's share price has been volatile over the past 3 months.
Volatility Over Time: 0P0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.
Aerie Pharmaceuticals, Inc. Fundamentals Summary
| 0P0 fundamental statistics | |
|---|---|
| Market cap | €735.53m |
| Earnings (TTM) | -€35.68m |
| Revenue (TTM) | €208.81m |
3.5x
P/S Ratio-20.6x
P/E RatioIs 0P0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0P0 income statement (TTM) | |
|---|---|
| Revenue | US$213.94m |
| Cost of Revenue | US$23.52m |
| Gross Profit | US$190.42m |
| Other Expenses | US$226.98m |
| Earnings | -US$36.55m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 89.01% |
| Net Profit Margin | -17.09% |
| Debt/Equity Ratio | -190.6% |
How did 0P0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/21 20:55 |
| End of Day Share Price | 2022/11/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aerie Pharmaceuticals, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Difei Yang | Brean Capital |
| John Newman | Canaccord Genuity |